EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a

Xinting Wang iD, Jiahui Yang, Cheng Lu, Yinqin Hu iD, Zhaohui Xu, Qiqi Wan, Meng Zhang, Tianyun Shi, Zhirui Liu, Yongming Liu

Drug Design, Development and Therapy · 2024-03 · Volume 18 · 781-799

DOI: 10.2147/dddt.s446324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024-03. Verfasst von Xinting Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, People's Republic of…. Hauptthemen laut MEDLINE: Sumoylation, Heart Failure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to elucidate the protective mechanism of Traditional Chinese Medicine (TCM) Qifu Yixin formula (QFYXF) to improve heart failure (HF) by promoting β-arrestin2 (β-arr2)-mediated SERCA2a SUMOylation. Materials and Methods: The transverse aortic constriction (TAC)-induced HF mice were treated with QFYXF or carvedilol for 8 weeks. β-arr2-KO mice and their littermate wild-type (WT) mice were used as controls. Neonatal rat cardiomyocytes (NRCMs) were used in vitro. Cardiac function was evaluated by echocardiography and serum NT-proBNP. Myocardial hypertrophy and myocardial fibrosis were assessed by histological staining. β-arr2, SERCA2a, SUMO1, PLB and p-PLB expressions were detected by Western blotting, immunofluorescence and immunohistochemistry. SERCA2a SUMOylation was detected by Co-IP. The molecular docking method was used to predict the binding ability of the main active components of QFYXF to β-arr2, SERCA2a, and SUMO1, and the binding degree of SERCA2a to SUMO1 protein.

Results

The HF model was constructed 8 weeks after TAC. QFYXF ameliorated cardiac function, inhibiting myocardial hypertrophy and fibrosis. QFYXF promoted SERCA2a expression and SERCA2a SUMOylation. Further investigation showed that QFYXF promoted β-arr2 expression, whereas Barbadin (β-arr2 inhibitor) or β-arr2-KO reduced SERCA2a SUMOylation and attenuated the protective effect of QFYXF improved HF. Molecular docking showed that the main active components of QFYXF had good binding activities with β-arr2, SERCA2a, and SUMO1, and SERCA2a had a high binding degree with SUMO1 protein.

Conclusion

QFYXF improves HF by promoting β-arr2 mediated SERCA2a SUMOylation and increasing SERCA2a expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SumoylationHeart FailureRatsMiceAnimalsMolecular Docking SimulationMyocytes, CardiacCardiomegaly

Stichwörter der Autor:innen

Qifu Yixin FormulaSERCA2aSUMOylationheart failureβ-arrestin2

Autor:innen und Institutionen

  • Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, People's Republic of China.
  • Department of Cardiology, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, People's Republic of China.

ORCID-Profile: Xinting Wang, Yinqin Hu

Zitieren

APA

Wang, X., Yang, J., Lu, C., Hu, Y., Xu, Z., Wan, Q., Zhang, M., Shi, T., Liu, Z., & Liu, Y. (2024). Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a. Drug Design, Development and Therapy, Volume 18, 781-799. https://doi.org/10.2147/dddt.s446324

Vancouver

Wang X, Yang J, Lu C, Hu Y, Xu Z, Wan Q, et al. Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a. Drug Design, Development and Therapy. 2024;Volume 18:781-799. doi:10.2147/dddt.s446324

BibTeX
@article{Wang2024,
  author = {Wang, Xinting and Yang, Jiahui and Lu, Cheng and Hu, Yinqin and Xu, Zhaohui and Wan, Qiqi and Zhang, Meng and Shi, Tianyun and Liu, Zhirui and Liu, Yongming},
  title = {Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  volume = {Volume 18},
  pages = {781--799},
  doi = {10.2147/dddt.s446324}
}
Kostenlos starten →